- Q3 2026 net income of $20.4M ($0.07/share) versus net loss of $42.2M ($0.16/share) in Q3 2025
- 9M 2026 net loss narrowed to $90.4M from $185.3M in prior year period
- Reported progress toward initiating Phase 1/2 SC451 trial and SG293 clinical study
Why is $SANA moving today? · SEC 8-K archive
$SANA SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $SANA: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $SANA filing catalyst
Why did $SANA trigger an AI stock catalyst alert?
$SANA triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.5/10). Headline: Sana Biotechnology Q3 2026: Swings to Net Income of $20.4M or $0.07 Per Share. Key points: - Q3 2026 net income of $20.4M ($0.07/share) versus net loss of $42.2M ($0.16/share) in Q3 2025 - 9M 2026 net loss narrowed to $90.4M from $185.3M in prior year period - Reported progress toward initiating Phase 1/2 SC451 trial and SG293 clinical study
How did $SANA stock react after the SEC filing?
After the SEC 8-K for $SANA, observed market reaction: T0 price $2.34. Past moves do not guarantee future results.
Where can I get real-time $SANA SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $SANA via Telegram and the VIP Web Terminal from €10/month.